MDPI and ACS Style
Casili, G.; Scuderi, S.A.; Lanza, M.; Filippone, A.; Mannino, D.; Giuffrida, R.; Colarossi, C.; Mare, M.; Capra, A.P.; De Gaetano, F.;
et al. Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796. Cancers 2024, 16, 1211.
https://doi.org/10.3390/cancers16061211
AMA Style
Casili G, Scuderi SA, Lanza M, Filippone A, Mannino D, Giuffrida R, Colarossi C, Mare M, Capra AP, De Gaetano F,
et al. Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796. Cancers. 2024; 16(6):1211.
https://doi.org/10.3390/cancers16061211
Chicago/Turabian Style
Casili, Giovanna, Sarah Adriana Scuderi, Marika Lanza, Alessia Filippone, Deborah Mannino, Raffaella Giuffrida, Cristina Colarossi, Marzia Mare, Anna Paola Capra, Federica De Gaetano,
and et al. 2024. "Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796" Cancers 16, no. 6: 1211.
https://doi.org/10.3390/cancers16061211